[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemiparesis-after-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemiparesis-after-stroke":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,44,71,113,142,176,199,223,249],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100604747","spinal-cord-stimulation-combined-with-physical-therapy-in-post-stroke-upper-limb-motor-hemiparesis-100604747",false,"NCT07153536","Spinal Cord Stimulation Combined With Physical Therapy in Post-Stroke Upper-Limb Motor Hemiparesis","Inclusion Criteria:\n\n1. Experienced an ischemic or hemorrhagic stroke that resulted in arm and hand hemiparesis more than 6 months prior to the time of enrollment (Prior strokes that did not cause upper extremity motor deficits are not exclusionary.)\n2. Age 22 to 70 years old\n3. Upper extremity motor score higher than 20 and lower than or equal to 45 on the Fugl-Meyer Assessment (FMA) scale\n4. FMA upper extremity sensory score higher than 6 points (out of 12 points)\n5. The ability to communicate, understand, give appropriate consent and follow two-step commands\n\nExclusion Criteria:\n\n1. Presence of any serious disease or disorder (ex. Neurological conditions other than stroke, cancer, severe cardiac or respiratory disease, renal failure, etc.) that could affect their ability to participate in this study\n2. Considered to be at high-risk of recurrent stroke as evident from their medical history or upon judgment of the study physician\n3. Presence of post-stroke central pain, other forms of pain or other constraints such as joint contractures in the paretic arm that are serious enough to prevent or affect the correct execution of the physical training protocol as judged by the study therapist\n4. A score on the Short Blessed Test assessment scale lower than 9\n5. Female participants of child-bearing age who are pregnant or breastfeeding during the study\n6. Participants that cannot suspend their antiplatelets and\u002For anticoagulant therapy for two weeks around the time of surgery\n7. Existence of any implanted medical device that is not MRI safe and\u002For any active medical devices even if it is MRI safe\n8. Implanted spinal fusion and stabilization devices such as plates and rods between the C2 and T3 spinal vertebra\n9. Obstructed or restricted epidural spinal canal to the point of hindering or increasing the risk of implant of the spinal leads as judged by the study surgeon upon screening imaging\n10. Severe claustrophobia that prevents execution of the required MRI imaging sessions\n11. Taking anti-spasticity or anti-epileptic medications\n12. T-score higher than 63 on the 18-question Brief Symptoms Inventory (BSI-18) who have undergone discussions with and been deemed unsuitable by the Principal Investigator and a study physician\n\nPotential participants who may be excluded on initial screening may discuss possible medication changes with their physician.","ALL","22 Years","70 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study plans to use systems that have been developed by Medtronic to investigate the use of cervical spinal cord stimulation to treat adults with upper limb hemiparesis resulting from a stroke. The spinal cord stimulation (SCS) will be combined with physical training to improve arm and hand motor control. The study is divided into three phases. In the first phase, after baseline assessments, participants will undergo a Physical Training Protocol (PTP) for 6 weeks including 3 sessions of 90 mins\u002Fsession per week. After receiving the Medtronic implantable system, in Phase 2, they will then repeat the same PTP program in combination with spinal cord stimulation during the entirety of each of the rehabilitation sessions. Finally, in Phase 3, participants will go home, will not be able to use the stimulation at home but will participate in monthly assessments in the laboratory in which the functionality of the Medtronic system and their motor performances will be assessed for up to 6 months.",[26,27,28],"Stroke","Spinal Cord Injuries and Disorders","Hemiparesis After Stroke",[30],"spinal cord stimulation","RECRUITING","2026-06-17",{"date":34,"type":35},"2026-06-22","ACTUAL",{"date":37,"type":35},"2026-01-06",{"date":39,"type":20},"2028-01-01",{"name":41,"class":42},"Marco Capogrosso","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":43},"100642638","radiographic-cortical-thickness-of-the-humerus-in-detecting-post-stroke-regional-bone-loss-100642638","NCT07651306","Radiographic Cortical Thickness of the Humerus in Detecting Post-Stroke Regional Bone Loss","Inclusion Criteria:\n\n* Patients aged 18 years and older.\n* A documented history of a single unilateral stroke that occurred at least 6 months prior to evaluation.\n* Presence of clinical hemiparesis.\n* Availability of concurrent standard anteroposterior (AP) shoulder radiographs taken within 6 months post-stroke alongside systemic DXA measurements.\n\nExclusion Criteria:\n\n* History of surgical intervention in either shoulder. History of a proximal humerus fracture.\n* Co-existing metabolic bone diseases, such as primary hyperparathyroidism or osteomalacia.\n* History of malignancy.\n* Documented history of corticosteroid use.\n* Imaging artifacts that compromise the accuracy of DXA measurements.\n* History of a secondary stroke.","18 Years",{"count":52,"type":20},65,"OBSERVATIONAL","Post-stroke immobilization and reduced weight-bearing frequently lead to significant regional bone mineral density loss and asymmetry, particularly in the paretic upper extremity, which increases fracture risks. While Dual-Energy X-ray Absorptiometry (DXA) is the gold standard for evaluating systemic bone loss, it primarily focuses on axial or lower extremity sites and lacks universal accessibility. Since routine shoulder radiographs offer an opportunistic screening tool to evaluate regional bone quality without additional radiation , this study aims to compare proximal humerus cortical bone thickness between the paretic and non-paretic sides in stroke patients and assess its correlation with systemic DXA values to determine its clinical utility.\n\nThis cross-sectional, observational study involves a retrospective data analysis of patients aged 18 and older who experienced a single unilateral stroke at least 6 months prior and present with clinical hemiparesis. Eligible participants must have concurrent standard anteroposterior shoulder radiographs and DXA measurements available from their routine clinical follow-ups. Patient demographic data, stroke characteristics, Brunnstrom stages, and systemic DXA measurements (femoral neck and lumbar spine T-scores and bone mineral density values) are systematically recorded for analysis.\n\nCortical bone thickness measurements are performed using ImageJ software on standard radiographs at points 10 cm and 12 cm distal to the highest point of the humerus. To ensure reliability, measurements for both the paretic and non-paretic sides are conducted independently by two researchers who are completely blinded to the DXA results. Statistical analyses, including paired t-tests or Wilcoxon tests and Pearson or Spearman correlations, will be used to compare the sides and evaluate the relationship between radiographic cortical thickness and systemic bone density.",[28,56,57],"Dual Energy X-ray Absorptiometry","Osteoporosis",[26,59,57,60],"Cortical Bone Thickness","Radiography","2026-06-12",{"date":63,"type":35},"2026-06-16",{"date":65,"type":35},"2026-02-22",{"date":67,"type":20},"2026-07-01",{"name":69,"class":70},"Istanbul Physical Medicine Rehabilitation Training and Research Hospital","OTHER_GOV",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":81,"conditions":82,"keywords":93,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":43},"100597086","phase-1-psychedelic-healing-adjunct-therapy-harnessing-opened-malleability-100597086","NCT07053917","Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability","PHATHOM","Inclusion Criteria:\n\n* Over age 18 years, inclusive.\n* Ischemic or hemorrhagic stroke confirmed by CT or MRI, at least 12 months prior to admission date\n* Ability to give informed consent and understand the tasks involved.\n* Agree that, for the study duration, will refrain from: (1) No new prescription medications during the time of the study without approval of the study team, (2) taking any herbal supplement (except with prior approval of the research team), (3) taking any nonprescription medications with the exception of: 1. non-steroidal anti-inflammatory drugs. 2. acetaminophen. 3. vitamins. 4. or other over-the-counter medications approved by the research team\n* Are willing to follow restrictions and guidelines concerning medications, consumption of food, beverages, and nicotine the night before and just prior to psilocybin administration.\n* Agree to have transportation other than driving themselves home or to where the participants are staying after the administration of psilocybin.\n* Are willing to be contacted via telephone for all necessary telephone contacts.\n* Must have a negative pregnancy test if able to bear children.\n* Must provide a contact (relative, spouse, close friend or other caregiver) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal.\n* Must agree to inform the investigators within 48 hours of any new medical conditions and procedures.\n* Are proficient in speaking and reading English.\n* Agree to have all clinical visit sessions recorded to audio and video.\n* Agree to not participate in any other interventional clinical trials during the duration of this study.\n\nExclusion Criteria:\n\n* Taking one of the following medications in the 30 days prior to psilocybin administration:\n\n  1. selective serotonin reuptake inhibitor (SSRI)\n  2. Serotonin-norepinephrine reuptake inhibitors (SNRI)\n  3. Buproprion\n  4. Valproic acid\n  5. Zolpidem\n  6. Trazodone\n  7. Carbamazepine.\n  8. tricyclic antidepressants\n  9. Monoamine Oxidase Inhibitors\n  10. Mirtazapine\n\n  l. Lithium m. Buspirone n. Atypical antipsychotics o. Zolpidem p.Carbamazepine q. Clonazepam r. Gabapentin s. Lamotrigine t. Levetiracetam u. Phenobarbital v. Phenytoin w. Topiramate x. Valproic Acid y. Zonisamide\n* History of medically significant suicide attempt.\n* Evidence of acute cardiac dysfunction as evidenced by either elevated troponin or EKG changes within 48 hours of administration.\n* Systolic blood pressure that is greater than 150 mmHg systolic on \\> 2 readings during the 7-day monitoring period AND blood pressure medication management has been assured.\n* Diastolic blood pressure that is greater than 100 mmHg systolic on \\> 2 readings during the 7-day monitoring period AND blood pressure medication management has been assured.\n* Systolic blood pressure is less than 90 mmHg systolic on \\> 2 readings during the 7-day monitoring period after blood pressure medication management has been assured.\n* Diastolic blood pressure is less than 30 mmHg systolic on \\> 2 readings during the 7-day monitoring period after blood pressure medication management has been assured.\n* Systolic blood pressure exceeds 160 mmHg or is less than 90 mmHg immediately prior to administration of psilocybin; patients are allowed to be on anti-hypertensives.\n* Diastolic blood pressure exceeds 100 mmHg or is less than 30 mmHg immediately prior to administration of psilocybin; patients are allowed to be on anti-hypertensives.\n* Cognitive impairment that, in the estimation of the study team, would preclude the use of the MindPod Dolphin.\n* History of physical or neurological condition that interferes with study procedures or assessment of motor function (e.g. severe arthritis, severe neuropathy, Parkinson's disease).\n* Social and\u002For personal circumstances that interfere with ability to perform follow up assessments.\n* Are pregnant or nursing.\n* Weigh less than 48 kg.\n* Are not able to give adequate informed consent.\n* Are actively abusing opioids, cocaine, Phencyclidine (PCP), amphetamines, or alcohol.\n* Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (SCID-5) criteria for moderate or severe substance use disorder\n* Diagnosis of schizophrenia, history of prior psychosis, anxiety requiring hospitalization, or Type 1 bipolar.\n* Hypernatremia\n* Hypokalemia (but can have received repletion during the prior 24 hours)\n* Hyperkalemia\n* Glomerular filtration rate of \\\u003C 30 ml\u002Fmin\n* Elevated of white blood cell count\n* Hemoglobin \\\u003C 7 g\u002Fdl\n* Platelet count \\\u003C 100,000 g\u002Fdl\n* Acute cardiac dysfunction demonstrated by either troponin elevation (chronic elevation is acceptable), or EKG changes suggestive of acute coronary syndrome.\n* Active suicidal ideation as assess by the C-SSRS.",{"count":19,"type":20},[80],"PHASE1","The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.",[26,83,84,85,86,87,88,28,89,90,91,92],"Chronic Stroke","Intracerebral Haemorrhage","Intracerebral Haemorrhage (ICH)","Intracerebral Hemorrhage Basal Ganglia","Ischemic Stroke","Ischemic Stroke and Hemorrhagic Stroke","Hemiplegia Following Ischemic Stroke","Hemiplegia and Hemiparesis","Hemiplegia and\u002For Hemiparesis Following Stroke","Middle Cerebral Artery Stroke",[94,95,96,97,98,99,100,101,102,103],"psychedelic","stroke","chronic stroke","intracerebral hemorrhage","stroke recovery","motor recovery","poststroke recovery","poststroke motor recovery","hemiparesis recovery","psychedelic safety","2026-02-11",{"date":106,"type":35},"2026-02-13",{"date":108,"type":35},"2026-02-09",{"date":110,"type":20},"2027-03",{"name":112,"class":42},"Johns Hopkins University",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":15,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":21,"phases":125,"briefSummary":126,"conditions":127,"keywords":128,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100614778","the-impact-of-neuronavigation-in-rtms-for-hemiplegic-stroke-patients-100614778","NCT07284017","The Impact of Neuronavigation in rTMS for Hemiplegic Stroke Patients.","The Impact of Neuronavigation in Repetitive Transcranial Magnetic Stimulation (rTMS) for Hemiplegic Stroke Patients.","NeurorTMS-HS","Inclusion Criteria:\n\n* First-ever ischemic or hemorrhagic stroke confirmed by imaging.\n* Stroke causing unilateral upper limb weakness (MRC grade \\\u003C=3)\n* Stroke onset must be between 2 weeks and 6 months prior to enrollment (subacute phase).\n* Age between 20 and 85 years old.\n* Stable vital signs, clear consciousness, and no cognitive impairment.\n* Able to cooperate with assessments and treatment.\n* Written informed consent must be signed by the patient or a legal guardian.\n\nExclusion Criteria:\n\n* Contraindications to TMS (e.g., metallic implants in head, pacemaker, cochlear implant).\n* History of epilepsy or seizures.\n* Pregnancy.\n* Severe cognitive or communication disorders, or inability to give informed consent.\n* Unstable medical conditions affecting participation.\n* Use of certain medications, including benzodiazepines, antidepressants, muscle relaxants (baclofen, tizanidine), or ongoing botulinum toxin injections for post-stroke spasticity.\n* Modified Rankin Scale (mRS) score \\>=5 .","20 Years","85 Years",{"count":124,"type":20},30,[23],"This is a randomized, controlled trial investigating the efficacy and precision of neuronavigation -guided repetitive transcranial magnetic stimulation (rTMS) for motor recovery in patients with subacute stroke hemiparesis.\n\nThe primary goal is to determine if using neuronavigation to precisely target the unaffected primary motor cortex (M1) improves treatment accuracy, efficiency, and clinical outcomes compared to conventional manual positioning.\n\nThe study will enroll 30 participants with first-ever stroke onset between 2 weeks and 6 months. Participants will be randomized into two parallel groups: the Experimental Group (neuronavigation-guided rTMS) and the Control Group (conventional positioning rTMS). Both groups will receive the same rTMS parameters: 1 Hz stimulation (low-frequency) over the unaffected M1, 1,200 pulses per session, administered for 10 sessions over 2 consecutive weeks.\n\nPrimary outcome measures include the change in the Fugl-Meyer Assessment (FMA) Score for the Upper Extremity and the measurement of coil positioning deviation between sessions. Assessments will be conducted at baseline (T0), post-treatment (T1, Week 3), and one month post-treatment (T2, Week 7). This study is funded in part by a research grant from the Metal Industries Research \\& Development Centre (MIRDC).",[26,28],[129,130,131],"rTMS","Repetitive Transcranial Magnetic Stimulation","Neuronavigation","NOT_YET_RECRUITING","2025-12-14",{"date":135,"type":35},"2025-12-16",{"date":137,"type":20},"2026-01-01",{"date":139,"type":20},"2026-12-31",{"name":141,"class":42},"Taichung Veterans General Hospital",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":152,"briefSummary":153,"conditions":154,"keywords":158,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":43},"100598573","effects-of-intermitted-theta-burst-stimulation-itbs-on-motor-recovery-of-upper-extremity-in-chronic-stroke-patients-100598573","NCT07073248","Effects of Intermitted Theta Burst Stimulation (iTBS) on Motor Recovery of Upper Extremity in Chronic Stroke Patients","Neuroplastic Changes and Effects of Intermittent Theta Burst Stimulation (iTBS) on Motor Recovery of Upper and Lower Extremity in Chronic Stroke Patients","NIMBLE","Inclusion Criteria:\n\n* Age over 18\n* Chronic stroke (\\>6 months)\n* Residual hemiparesis FM-UE\\>17\n\nExclusion Criteria:\n\n* Metal implants\n* Epilepsy\u002Fseizures\n* Pregnancy\n* Claustrophobia (related to MRIs exams)\n* Severe cognitive impairment\n* Untreated or unstable depression\u002Fanxiety\n* Other disabilities prohibiting intensive physical training",{"count":151,"type":20},48,[23],"This study aims to evaluate the effects and clinical feasibility of non-invasive brain stimulation protocols, specifically intermittent Theta Burst Stimulation, as part of rehabilitation interventions for motor recovery of upper extremity in the chronic phase after stroke.\n\nIt also seeks to explore the underlying mechanisms by investigating changes of functional and structural brain networks.",[26,155,28,156,157],"Hemiplegia","Hand Functionality","Chronic Stroke Patients",[95,159,160,161,162,163,164,165,166],"iTBS","TMS","Motor cortex","chronic stroke patients","hand dexterity","Hemiparesis","Transcrania Magnetic Stimulation","intermittent Theta Burst Stimulation","2025-11-20",{"date":169,"type":35},"2025-11-21",{"date":171,"type":20},"2025-11",{"date":173,"type":20},"2030-12",{"name":175,"class":42},"Danderyd Hospital",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":147,"acronym":148,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":21,"phases":184,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":197,"leadSponsor":198,"locationsCount":43},"100598572","effects-of-intermittent-theta-burst-stimulation-itbs-on-motor-recovery-of-lower-extremity-in-chronic-stroke-patients-100598572","NCT07073235","Effects of Intermittent Theta Burst Stimulation (iTBS) on Motor Recovery of Lower Extremity in Chronic Stroke Patients","Inclusion Criteria:\n\n* Age over 18\n* Chronic stroke (\\>6 months)\n* Residual hemiparesis FAC ≥3\n\nExclusion Criteria:\n\n* Metal implants\n* Epilepsy\u002Fseizures\n* Pregnancy\n* Claustrophobia (related to MRIs exams)\n* Severe cognitive impairment\n* Untreated or unstable depression\u002Fanxiety\n* Other disabilities prohibiting intensive physical training",{"count":183,"type":20},56,[23],"This study aims to evaluate the effects and clinical feasibility of non-invasive brain stimulation protocols, specifically intermittent Theta Burst Stimulation, as part of rehabilitation interventions for motor recovery of lower extremity in the chronic phase after stroke.\n\nIt also seeks to explore the underlying mechanisms by investigating changes of functional and structural brain networks.",[26,28,157,155,187],"Ambulatory Difficulty",[95,159,160,189,190,191,192,193,164,166],"Trancranial Magnetic Stimulation","Cerebellum","Chronic stroke patients","Balance","Walking",{"date":195,"type":35},"2025-11-25",{"date":171,"type":20},{"date":173,"type":20},{"name":175,"class":42},{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":15,"minAge":207,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":21,"phases":211,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":43},"100572661","post-stroke-ambulation-recovery-using-robotic-exoskeletons-100572661","NCT06736171","Post Stroke Ambulation Recovery Using Robotic Exoskeletons","Prescription of Robotic Exoskeletons for Ambulation Recovery Post Stroke","RERC","Inclusion Criteria:\n\n* Stroke survivors 3 - 8 months from a recent stroke.\n* Age: 50 - 80 years\n* Unilateral hemiparesis\n* Medical clearance by the Medical Director\n* Be able to physically fit into the exoskeleton device: Height between 60\\" and 76\\" and weight below 220 lbs\n* Patient cognitive status and ability to communicate in English must be at a level consistent with that required to participate in standard motor rehabilitation (e.g. can follow directions).\n* Adequate cognitive function to give informed consent, understand the training, instructions, use investigational devices and give adequate feedback.\n* Have a joint range of motion within normal functional limits for ambulation.\n* Have sufficient strength to use the hemiwalker, cane or walker (etc. assistive device) while wearing the RE.\n* No history of injury or pathology to the unaffected limb.\n* Have an appropriate walking speed as determined by the study staff.\n\nExclusion Criteria:\n\n* Any medical issue that precludes full weight-bearing and ambulation (e.g. orthopedic injuries, pain, severe spasticity).\n* Skin issues that would prevent wearing the device.\n* Pre-existing condition that caused exercise intolerance (documented uncontrolled hypertension, coronary artery disease, cardiac arrhythmia, or congestive heart failure).\n* Hospitalization for heart attack, heart surgery, or acute heart failure within 3 months of enrollment in the study.\n* Uncontrolled seizure disorder, spasticity, or joint contracture that would interfere with walking.\n* Neuromuscular, neurological, or orthopedic pathologies that interfere with neuromuscular function, ambulation, or limit the range of motion of the lower limbs.","50 Years","80 Years",{"count":210,"type":20},96,[23],"The purpose of this research study is to evaluate and compare different robotic exoskeletons (RE) and identify which is most appropriate for gait training for each patient based off their specific needs. This will help guide clinicians in prescribing the appropriate RE for rehabilitation.",[28],"2025-08-25",{"date":216,"type":35},"2025-09-02",{"date":218,"type":35},"2025-05-15",{"date":220,"type":20},"2030-06",{"name":222,"class":42},"Kessler Foundation",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":122,"enrollmentInfo":229,"targetDuration":231,"studyType":53,"phases":4,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":246,"locationsCount":4},"100604312","prospective-real-world-evidence-study-of-the-ipsihand-system-in-adult-stroke-survivors-100604312","NCT07147881","Prospective Real-World Evidence Study of the IpsiHand® System in Adult Stroke Survivors","Inclusion Criteria:\n\n1. Adult age 18-85 years.\n2. Diagnosis of stroke six or more months prior with upper extremity weakness.\n3. Has received an IpsiHand® system as a commercial customer for stroke rehabilitation.\n\nExclusion Criteria:\n\n1. Severe cognitive impairment that would impede utilization of IpsiHand®\n2. Any contraindications to IpsiHand® device use\n3. Inability to comprehend English",{"count":230,"type":20},100,"2 Years","This study focuses on monitoring real-world customers who have been prescribed the IpsiHand® as part of their rehabilitation post-stroke. This study aims to evaluate their progress over time, assessing motor recovery, functional independence in activities of daily living (ADLs), caregiver burden, and health economic outcomes.",[26,28,234],"Brain Computer Interface",[236,237,26,238,239],"Neurolutions","IpsiHand","Hemiparesis after stroke","BCI","2025-08-22",{"date":242,"type":35},"2025-08-29",{"date":244,"type":20},"2025-09-01",{"date":39,"type":20},{"name":247,"class":248},"Neurolutions, Inc.","INDUSTRY",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":21,"phases":259,"briefSummary":260,"conditions":261,"keywords":263,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":43},"100592944","combined-aphasia-and-robot-assisted-arm-treatment-for-chronic-stroke-survivors-100592944","NCT07000019","Combined Aphasia and Robot-Assisted Arm Treatment for Chronic Stroke Survivors","CARAT","Inclusion Criteria:\n\n1. Male or female patients between 18-90 years of age.\n2. Right-handed prior to stroke\n3. English-speaking (monolingual)\n4. History of single left-hemisphere stroke at least 6 months prior to enrollment\n5. Presence of aphasia and naming deficits on Western Aphasia Battery (WAB-R)\n6. Comprehension score above 4 on WAB-R\n7. Unilateral upper limb paresis (Fugl-Meyer Upper Extremity score \\\u003C56)\n8. Documentation of signed Informed Consent by the study participant.\n\nExclusion Criteria:\n\n1. Diagnosis or history of speech impairment prior to stroke\n2. Severely limited speech output (score below 2 on spontaneous speech portion of WAB-R)\n3. Inability to perform screening tasks due to severe language and\u002For cognitive impairment\n4. Condition limiting passive movement in the range of motion required for robotic therapy (e.g. fixed contracture)\n5. Any medical or psychiatric condition that may impact participation or compliance with study procedures or activities in the opinion of the investigator","90 Years",{"count":258,"type":20},28,[23],"The goal of this clinical trial is to learn if a program that combines language and arm treatment can improve language and movement problems in people with chronic stroke. The mains questions it aims to answer are:\n\n* To determine the extent to which this combined treatment can improve language.\n* To determine the extent to which the combined treatment can improve arm movements.\n\nResearchers will compare the effects of this combined treatment with treatment that targets arm movements alone.",[26,262,28],"Aphasia Following Cerebral Infarction",[264],"stroke, aphasia, hemiparesis, robotic","2025-05-23",{"date":267,"type":35},"2025-05-31",{"date":269,"type":20},"2025-06",{"date":271,"type":20},"2027-11",{"name":273,"class":42},"New York Medical College"]